Widespread evidence supports the existence of an endogenous digitalis-like compound in mammals. We report here the development of a novel enzyme immunoassay for ouabain that, in conjunction with a detailed HPLC study, identifies a ouabain-like compound (OLC) in extracted human plasma. The assay is sensitiveminimum detection limit for OLC 37 pmol/L (11 pmol/L in plasma)-and has a working range (between-assay CV <10%) of 180 -10 000 pmol/L (54 -3000 pmol/L in plasma). Mean recoveries of ouabain added to plasma ranged from 90% to 100%, and plasma extracts diluted in parallel to the standard curve. Plasma OLC concentrations in 10 healthy volunteers averaged 92 pmol/L (range 55-168), assuming 100% cross-reactivity of OLC in the ouabain assay. HPLC analysis with two distinct chromatographic conditions demonstrated that endogenous human plasma OLC co-eluted with authentic ouabain. The enzyme immunoassay is rapid and easy to perform and will support further investigation of the nature of this controversial endogenous steroid.
The presence of endogenous factors with digitalis-like immunoreactivity in mammals has been frequently documented [1, 2] . Hamlyn et al. [3] [4] [5] [6] [7] proposed that an endogenous digitalis-like factor isolated from human plasma was ouabain or a closely related isomer. The same group has recently reported that the site of synthesis of the ouabain-like compound (OLC) is the adrenal zona glomerulosa [8] . 4 Other groups have also identified OLC in human plasma [9 -11] , rat and human urine [12, 13] , and bovine hypothalamus [14] .
The physiological role of OLC is unknown. Ouabain has a strong affinity for the integral membrane sodiumpotassium pump, Na ϩ ,K ϩ -ATPase [15] . Blaustein [16] suggested that the binding of ouabain to this pump leads to numerous physiological and pathophysiological events, including an increase of calcium release on cell activation. Ouabain at pathophysiological concentrations (1 nmol/L) substantially increased intracellular calcium concentrations in cultured rat vascular smooth muscle cells [17] . OLC is thought to have a role in the pathogenesis of essential hypertension [18, 19] , and concentrations of OLCs are above normal in subjects with essential hypertension [9, 20] .
The notion of an endogenous OLC has met with skepticism [21, 22] . OLC biosynthesis, release, and sites of production are little understood. Lewis et al. [23] indicated that the immunoreactive compound extracted from human plasma was not ouabain because it did not coelute with pure ouabain on HPLC and Doris et al. [24] found only small amounts of OLC in a minority of the healthy volunteers studied. However, Di Bartolo et al. [11] detected OLC in human plasma from newborns, which coelutes with authentic ouabain and, like ouabain, inhibits 86 Rb uptake; moreover, the addition of anti-ouabain antibodies reverses this inhibitory effect. Investigations with ouabain and OLC by Zhao et al. [25] , using HPLC and circular dichroism, suggest that OLC is very similar to but not identical with authentic ouabain. Differences in antibody specificity for OLC may account for some of these conflicting results.
Few assays have been described in the literature for the detection of endogenous ouabain. Most tend to be laborintensive RIAs with tritiated ouabain [9, 24, 26 -29] . The ELISAs described by Harris et al. [6] and Gomez-Sanchez et al. [30] have many procedural advantages over the RIA methods, but have not been described in detail. We describe here a novel enzyme immunoassay (EIA) for endogenous OLC, giving full details of its development and of an extensive HPLC study showing that OLC in human plasma coelutes with authentic ouabain under two different chromatographic conditions.
Materials and Methods materials
Apparatus. HPLC Spherisorb C 8 column (4.6 mm ϫ 10 cm, 3-m particle size) was from Phase Separations, Deeside, Clwyd, UK. Hichrom RBP C 8 /C 18 HPLC column (4.6 mm ϫ 10 cm, 5-m particle size) was from Hichrom, Reading, Berks, UK, and C 18 solid-phase extraction cartridges (200 mg) were from Varian, Walton-on-Thames, Surrey, UK. The HPLC system consisted of an LKB (Bromma, Sweden) 2150 pump from Wallac UK, EG&G Instruments, Milton Keynes, UK, and a valve injector (Model 7725i) from Rheodyne, Cotati, CA. Multicalc software was obtained from Wallac UK.
Reagents. Ouabain octahydrate, dipotassium hydrogen phosphate, erythritol, 1,6-hexanediamine, sodium metaperiodate, horseradish peroxidase (HRP; Type II), 3,3Ј,5,5Ј-tetramethylbenzidine (TMB), and bovine serum albumin (BSA; Fraction V) were from Sigma Chemical Co., Poole, Dorset, UK. Sodium hydrogen carbonate, sodium dihydrogen orthophosphate, sodium acetate, citric acid, disodium hydrogen orthophosphate, Triton X-100, Tween 20, Brij 35, 2.5 mol/L sulfuric acid and concentrated hydrochloric acid (all AnalaR grade), 300 g/L hydrogen peroxide (AristaR), methanol, trifluoroacetic acid (TFA), acetonitrile, dimethyl sulfoxide (all Far UV or Spectrosol grade), and thin-layer chromatography plates (0.2 mm silica on aluminum) were from Merck, Lutterworth, Leic, UK. Donkey anti-rabbit IgG-coated microtiter plates were from Netria, London, UK; Freund's adjuvant from Difco Lab., Detroit, MI; and PD10 gel columns from Pharmacia Biotech, St. Albans, Herts, UK. Other chemicals were from Aldrich Chemical Co., Gillingham, Dorset, UK.
Solutions. Phosphate-buffered saline (PBS), pH 7.4, consisted of 20 mmol/L Na 2 HPO 4 , 5 mmol/L NaH 2 PO 4 , and 150 mmol/L NaCl. Assay diluent buffer (ADB) for the EIA consisted of 40 mmol/L Na 2 HPO 4 , 10 mmol/L NaH 2 PO 4 , 0.5 mL/L Tween 20, and 1 g/L gelatin, pH 7.4. EIA substrate solution consisted of 100 mmol/L sodium acetate, 2 mmol/L citric acid, 1.3 mmol/L hydrogen peroxide, pH 6.0, in AnalaR water. TMB reagent was stored at 42 mmol/L in dimethyl sulfoxide and was diluted 100-fold in substrate solution just before addition.
Calibrators. Because no pure human OLC was available, solutions of ouabain octahydrate ranging from 40 to 10 000 pmol/L were prepared in ADB and stored at Ϫ20°C for use as calibrators.
Samples. Blood was drawn from the antecubital vein and collected in 10-mL tubes containing EDTA. Plasma was separated immediately by centrifugation (16°C, 1400g, 10 min) and stored in 1.2-mL aliquots at Ϫ20°C. Samples were collected in accordance with the ethical requirements of our institution.
immunogen synthesis
The method used was a modified version of the protocol described by Harris et al. [6] , the major difference being that we used an oxime intermediate to facilitate the conjugation, whereas Harris et al. directly coupled ouabain dialdehyde to BSA-C 6 by using sodium cyanoborohydride.
Oxidation of ouabain.
We added 1 mL of distilled water and 670 L of acetone to 100 mg of ouabain octahydrate, warming the solution to 30 -40°C until all the ouabain dissolved. When the solution had cooled to ambient temperature, we added 75 mg of sodium metaperiodate. We then slowly added, over a 2-h period, 75 mg of K 2 HPO 4 to maintain pH between 7 and 8. To terminate the reaction, we added 8 mg of erythritol and stirred for 2 h. We removed volatile contaminants by rotary evaporation and dissolved the product in a mixture of methanol and dichloromethane (5 mL each). To this we added magnesium sulfate to remove any remaining water and filtered the solution through sintered glass with suction. Removal of the solvent by rotary evaporation yielded 87 mg of product, ouabain dialdehyde, as a white powder.
Formation of ouabain carboxymethyloxime. We dissolved ouabain dialdehyde (87 mg) in 5 mL of ethanol and then added 750 L of distilled water and 73 mg of carboxymethoxylamine hemihydrochloride. We added triethylamine (89 L) and monitored the reaction by thin-layer chromatography (developing solvent as before) for 80 min. We judged the reaction to be complete by the absence of starting material (Rf 0.8) and the presence of a single product spot (Rf 0.1). To this reaction mixture we added pyridine (400 L) to prepare for the addition of derivatized BSA.
Conjugation of BSA to hexanediamine. We dissolved 1 g of hexanediamine (C 6 ) in 10 mL of distilled water and adjusted to pH 8 with concentrated hydrochloric acid. BSA (260 mg) was then added and allowed to dissolve. Conjugation proceeded after addition of 300 mg of ethylcarbodiimide hydrochloride (EDC) in small portions every 15 min over a 6-h period. This mixture was stirred at room temperature for an additional 18 h and then dialyzed for 4 days against six 1-L changes of 30 mmol/L K 2 HPO 4 , pH 8.
Coupling ouabain carboxymethyloxime to BSA-C 6 . We added with gentle stirring 40 mg of the BSA-C 6 to the solution of ouabain carboxymethyloxime, and then added EDC: 30 mg over 4 h, an additional 15 mg over 1 h, and a final 15 mg. After the mixture had been stirred at room temperature for 18 h, we dialyzed it for 4 days against five changes of 1 L of distilled water and finally freeze-dried the final product to produce the desired immunogen (49.4 mg) as an off-white powder.
enzyme label synthesis
Oxidation of ouabain. We used sodium periodate to oxidize ouabain to the aldehyde as described above for the preparation of immunogen.
Conjugation to HRP.
We added 390 L of 0.1 mol/L NaHCO 3 reagent to 5.5 mg of ouabain dialdehyde, followed by 10 L of an aqueous solution of sodium cyanoborohydride (0.2 mol/L). We immediately added the resulting mixture to 5 mg of freeze-dried HRP, purified according to Tijssen and Kurstak [31] , and incubated the mixture in the dark for 4 h. To remove free ouabain from the ouabain-HRP conjugate, we used a PD10 gelfiltration column (prepacked with 8.5 mL of Sephadex G-25 and equilibrated with 50 mL of 0.1 mol/L NaHCO 3 ). After loading the reaction mixture onto the column, we added 1 mL of NaHCO 3 and discarded this first eluate. We repeated this with an additional 1 mL of NaHCO 3 , again discarding the eluate. After adding another 200 L of NaHCO 3 , we eluted the product (detected by the color of HRP) with 1.5 mL of NaHCO 3 , collecting the eluate in a glass vial. We diluted the product to 50 mL with 50 mmol/L sodium phosphate buffer, pH 7.4, containing 10 g/L BSA and 20 g/L mannitol, and freeze-dried this in 1-mL aliquots. We resuspended one of these aliquots in 2 mL of ADB and stored it in 50-L aliquots at Ϫ20°C. Just before assay, we diluted each aliquot 10 600-fold in ADB to give the working solution.
antibody production and assessment
We immunized four New Zealand White rabbits by intradermal injection with an emulsion of 1 mg of BSA-C 6 -ouabain in 1 mL of complete Freund's adjuvant, 100 L of 9 g/L NaCl solution, and 20 L of Brij 35, which we vortex-mixed for 30 min just before immunization. Subsequent immunizations (every 4 weeks) were with incomplete Freund's adjuvant. Animals were bled and serum was harvested 11 days after each immunization. We immunized two more rabbits by the same procedure but with 1 mg of BSA-C 6 in place of the immunogen, to obtain a control antiserum. To determine the anti-ouabain antibody titers from the immunized rabbit serum, we used doubling dilutions of rabbit antiserum in ADB and added to duplicate tubes 200 L of each antiserum dilution and 100 L (200 fmol) of [ 3 H]ouabain (200 fmol/100 L). All dilutions were vortex-mixed and then incubated for 21-24 h at 4°C. To separate the antibody bound and free fraction, we added 500 L of dextran-coated activated charcoal (10 g/L activated charcoal and 1 g/L dextran in assay buffer) to each tube (except those for total count), vortex-mixed the sample, and centrifuged them at 4°C for 15 min at 1400g. We decanted the supernatants into scintillation vials to which 4 mL of Ecoscint-A (National Diagnostic, Wessle, UK) was added. Each vial was then capped, shaken, and left in the dark for at least 90 min before counting radioactivity for 10 min. The titer (dilution at which binding is 50% of maximum) from the best-responding rabbit was found to increase with time, reaching a plateau at 1:12 000 after five immunizations. We used this antiserum at a dilution of 1:20 000 in the EIA. Antiserum from rabbits immunized with hapten only did not show any substantial binding to [ 3 H]ouabain.
sample pretreatment
The method was similar to that described by Harris et al. [6] . Frozen plasma samples were thawed and acidified with TFA to a final concentration of 1 mL/L, mixed, and centrifuged just before extraction. The C 18 solid-phase extraction columns were connected to a vacuum manifold (Varian), which we modified by replacing the metal delivery tips with plastic ones. The columns were initially activated with 6 mL of 400 mL/L acetonitrile in water containing 1 mL/L TFA; the solvent was removed by rinsing the column twice with 3 mL of 1 mL/L TFA in water. We then loaded 1 mL of an acidified plasma and removed any unbound material by five washes with 3 mL of 1 mL/L TFA in water. Ouabain was eluted in 5 mL of the acetonitrile/water/TFA solution. We dried the eluate under vacuum centrifugation at 55°C and resuspended the residues in 300 L of ADB before assay. This process concentrated the original plasma sample 3.3-fold. Samples for HPLC analysis followed the same protocol as above except that instead of eluting after the sample was loaded and washed through, we loaded an additional 1 mL of plasma onto the column, repeating this procedure until 5 mL of plasma had been loaded. Retained components were then eluted with 5 mL of the acetonitrile/ water/TFA solution. The eluate was dried as before and resuspended in 300 L of 0.5 or 0.2 mL/L TFA, depending on the mobile phase used. 1997 procedures EIA. We added (250 L/well) rabbit anti-ouabain antiserum diluted 1:20 000 in PBS to microtiter plates precoated with donkey anti-rabbit IgG. Each plate was incubated at 4°C in a constant-humidity chamber. After 2 h (or as long as 7 days) we washed the plates four times with PBS containing 0.1 mL/L Triton X-100 and dried them on a paper towel by tapping. We then added to each plate 50 L of calibrator/control/sample, followed by 200 L of enzyme-labeled ouabain working solution, and incubated these in the dark, with shaking, for 2 h at room temperature. We washed each plate four more times with PBS containing 0.1 mL/L Triton X-100 and dried it by tapping onto a paper towel before adding 200 L of TMB substrate reagent. Color was allowed to develop for 20 min before we terminated enzyme turnover by adding 50 L of 2.5 mol/L H 2 SO 4 . Absorbance was measured in a microplate spectrophotometer (Molecular Devices Vmax) at 450 nm (reference wavelength, 650 nm). We expressed results for endogenous OLC as pmol/L, assuming 100% cross-reactivity in the assay, which may or may not be correct. Therefore, the numerical values for OLC may or may not be accurate, but are correct as relative measures.
Clinical Chemistry
HPLC. For HPLC studies we used an isocratic reversedphase system and a C 8 or a C 8 /C 18 column run under different conditions. The mobile phase for the C 8 column was 70 mL/L acetonitrile in water containing 0.5 mL/L TFA and for the C 8 /C 18 column was 200 mL/L methanol containing 0.2 mL/L TFA. Flow rate for both columns was 1 mL/min. We calibrated the columns with authentic ouabain. Plasma extracts were obtained from four healthy subjects on C 18 columns as described earlier, resuspending the extract in 300 L of acidified water, mixing, and centrifuging before HPLC.
The test samples were loaded with a 50-L loop. Eluate fractions (1 mL) were dried by vacuum centrifugation at 55°C before resuspension in 300 L of assay buffer for measurement of ouabain immunoreactivity. To ensure that no ouabain remained from any exogenous source, we flushed through at least five blank samples-0.5 mL/L TFA (C 8 column) or 0.2 mL/L TFA (C 8 /C 18 column)-between each run and assayed the fractions.
Stability studies. To assess stability in whole blood, we collected blood from two healthy subjects into EDTA tubes. Plasma was separated by centrifugation (16°C, 1400g, 10 min) and frozen at Ϫ20°C at time 0 and subsequently at 1, 2, 4, 6, and 24 h after collection. On the day of extraction, samples were acidified and centrifuged as described in Sample pretreatment.
Results
Imprecision and working range. The working range for each assay was calculated with Multicalc software program version 1.5. To obtain an interassay precision profile, we pooled the data from 13 assays performed over 4 weeks.
The working range, as defined by a CV Ͻ10%, was 180 -10 000 pmol/L (Fig. 1) , or allowing for the 3.3-fold concentration effect of sample extraction, 54 -3000 pmol/L in the original plasma sample.
Minimum detectable concentration.
The lowest concentration that can be distinguished from zero by statistical criteria was calculated with Multicalc software program version 1.5 as the mean ϩ 3 SD of the response at zero interpolated from the calibration curve. Individual assay data were pooled (n ϭ 13) to give a mean Ϯ SD minimum detectable concentration of 37 Ϯ 11 pmol/L (range 21-57), equivalent to 11 Ϯ 3.3 pmol/L in the original plasma sample.
Analytical recovery. The mean recovery of 500 pmol/L ouabain added to plasma from five healthy subjects was 100% (range 84 -117%); for plasma from six renal transplant recipients, it was 99% (range 80 -119%). The mean recovery of 200 pmol/L ouabain added to plasma from five healthy subjects was 90% (range 87-93%).
Parallelism. Dilutions of plasma extracts from one healthy volunteer and one renal transplant recipient with normal renal function paralleled the calibration curve (Table 1) .
Specificity. We determined the cross-reactivity of various steroids and vasoactive compounds in the ouabain assay without prior extraction. To calculate cross-reactivity, we divided the concentration of cross-reacting material that inhibited 50% of the binding of the zero calibrator by the amount of ouabain that gave the same inhibition, expressed as a percentage (Table 2) . We detected no clinically critical cross-reactivity with any of the endogenous mammalian steroids tested although, by 40 weeks of gestation, serum progesterone concentrations could reach Values in plasma extracts, not corrected for the 3.3-fold concentration effect of the extraction procedure; e.g., an assay result of 180 pmol/L is equivalent to a plasma concentration of 54 pmol/L. 800 nmol/L-which at 0.015% cross-reactivity equates to a ouabain concentration of 120 pmol/L in this assay. However, recovery of exogenous progesterone (670 nmol/L) added to duplicate plasma samples before extraction was only 5% (35 nmol/L progesterone), illustrating no substantial cross-reactivity.
HPLC. HPLC of six extracted human plasma samples gave a single immunoreactive peak that coeluted with authentic ouabain. Retention times were 17 Ϯ 1 min (Fig.  2) for the C 8 column and 14 Ϯ 1 min (Fig. 3) for the C 8 /C 18 combination column. Recoveries of plasma OLC after HPLC ranged from 70% to 90%. To prevent carryover from one sample to the next, we extensively purged the column between assays. Before loading each plasma extract, we chromatographed a blank sample, which showed no evidence of containing detectable ouabain immunoreactivity.
Stability studies. OLC was stable in whole blood for 24 h at room temperature (Fig. 4) . CVs for plasma OLC concentrations in two healthy volunteers at the six storage time points were 9.4% and 8.8%, similar to the CV for 10 extractions of a single plasma sample in one assay.
Reference values for plasma OLC. Ten healthy human volunteers (five men, five women), mean age 28 years (range 26 -32), had a mean OLC concentration of 92 pmol/L (range 55-168), assuming 100% cross-reactivity of OLC in the ouabain assay.
Discussion
This novel EIA method for measuring OLC in plasma samples is quick, easy to perform with good precision, and able to detect endogenous OLC in human plasma. Donkey anti-rabbit IgG-coated microtiter plates can be coated with rabbit anti-ouabain antiserum at least 1 week Plasma extracts were serially diluted twofold in assay buffer. Results are corrected for the concentration effect of extraction and dilution factor. Flow rate was 1 mL/min, and 1-mL fractions were collected. Bar graphs show the concentration of OLC by immunoassay after HPLC of a ouabain calibrator, plasma supplemented with ouabain, and plasma extracts from four healthy subjects.
in advance, and an assay result can be achieved from extracted samples in Ͻ3 h. The assay characteristics are comparable with other published assays in terms of detection limits [6, 23, 24, 30] .
This assay is the most completely described immunoassay since the work of Harris et al. [6] . Our results confirm their findings in human plasma of an OLC that coelutes with authentic ouabain. This is important because other workers [23, 24] have not been able to reproduce the results of Hamlyn's group and therefore cast some doubt on their original findings. Our antiserum, like others described, recognized similar cardiac glycosides but cross-reacted little with endogenous steroids [6, 23, 24] . Cardiac glycosides have dimensions similar to the antibody binding site, and it is possible to examine the most important antigenic determinants for a given antiouabain antibody [32] . The poor cross-reactivity of dihydroouabain indicates that the unsaturated lactone ring is an essential recognition epitope. The rhamnose moiety, which is absent from ouabagenin, is less important, leading to only a partial reduction in immunoreactivity. Digoxin and digitoxin display marked differences in antibody binding, despite being practically identical (digitoxin lacks a hydroxyl group at C-12 on the steroid backbone). Ouabain and strophanthidin also do not contain a hydroxyl group at C-12, and it can be assumed that this site is important for antibody recognition. Collectively these data indicate that our assay detects a digitalislike compound, i.e., a cardenolide whose steroid moiety has the cis-trans-cis configuration between its ring junctions. The antiserum did not cross-react substantially with any of the endogenous mammalian steroids tested. The weak cross-reactivity of progesterone was clinically negligible after sample extraction because of the selectivity of the extraction technique.
Reported OLC concentrations in healthy subjects are 300 -1000 pmol/L [19, 26] , 40 pmol/L [9] , Ͻ75 pmol/L [24] , and Ͻ5 pmol/L [23] . The OLC concentrations detected by our EIA (ϳ100 pmol/L) are between these extremes. The differences could be partially due to assayand laboratory-dependent differences in calibration, extraction recovery, and antibody specificity (see below).
These HPLC results show that immunoreactive human plasma OLC has elution characteristics identical with ouabain under two different elution and separation conditions-further evidence that OLC is probably very similar structurally to authentic ouabain. This is in agreement with recent structural analyses of OLC from human plasma and bovine hypothalamus, which found that ouabain and OLC are structurally alike but not identical [14, 25] . Some groups [24, 30] have not been able to reproduce the original HPLC results [5] that showed ouabain coeluting with immunoreactive human OLC in an acetonitrile gradient. The difficulties associated with Plasma was separated and stored at Ϫ20°C at various timed intervals after collection (time axis is not to scale).
running reproducible gradient separations may explain this. Because our work with acetonitrile gradients gave erratic results (data not shown), we opted for an isocratic elution. Differences in antibody specificity are likely to be a major factor contributing to both the ability to detect OLC and its apparent concentration. If, as recent evidence suggests, OLC is not ouabain but a stereoisomer of ouabain, some anti-ouabain antiserum may cross-react with OLC far less than other antisera. Thus an OLC peak coeluting with ouabain might not be detected by antiouabain antibodies in some assay systems. Therefore, an antiserum with a very high specificity for ouabain, e.g., that described by Gomez-Sanchez et al. [30] , which showed minimal cross-reactivity for related cardiac glycosides, might prove less useful as an immunoassay reagent for detecting OLC than is the antiserum described here. These differences in specificity may result from the different procedures used for immunogen synthesisalthough all methods use ouabain conjugated to a carrier protein through the rhamnose moiety. The majority of groups who, like ourselves, have used [9, 11, 26] or partially used [6] a BSA-ouabain conjugate to raise an antiserum have achieved a higher degree of OLC detection than those using other conjugates of ouabain, e.g., linked to ovalbumin [23] or jack bean urease and porcine thyroglobulin [30] . However, Doris et al. [24] and Worgall et al. [29] , using an assay with an antiserum raised with a BSA conjugate, have both reported low or undetectable plasma OLC concentrations. The use of a spacer between ouabain and the carrier protein does not appear to confer a greater detection of OLC. Investigators who have not used a spacer include Masugi et al. [26] , who reported relatively high concentrations of OLC, and GomezSanchez et al. [30] , who could barely detect any OLC immunoreactivity. The reasons for the differences in ability to detect OLC are unclear.
In conclusion, this new, rapid, and easy-to-perform immunoassay for OLC has an obvious advantage over some of the other assay methods: its ability to detect OLC in measurable quantities. However, the degree of OLC cross-reactivity in our assay is unknown, and therefore its absolute accuracy is uncertain. Because human OLC dilutes in parallel with the ouabain calibration curve and because added ouabain can be recovered with great accuracy, we think it likely that OLC is highly crossreactive in our assay. However, until this and the other immunoassays have been calibrated with human OLC, all assigned OLC concentrations should be treated as relative measurements only and not necessarily be considered comparable between assays. The HPLC data indicate that the chromatographic characteristics of plasma OLC are identical with those of authentic ouabain, providing further evidence for structural similarity. Elucidation of the origin, bioactivity, and pathophysiological role of plasma OLC is the subject of ongoing studies. S.H. was supported during this study by the Joint Research Board, St. Bartholomew's Hospital.
